Completed PHASE3 INTERVENTIONAL 2-arm NCT00660075

Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes

Sponsor: Laval University

Conditions Diabetes Mellitus Postprandial Lipemia

Interventions Placebo Sitagliptin

Updated 9 times since 2017 Last updated: Nov 13, 2012 Started: Feb 29, 2008 Primary completion: Jan 31, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes Mellitus and Postprandial Lipemia and is currently completed. Laval University leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2022 — Dec 2022 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Laval University
Merck Sharp & Dohme LLC

Data source: Laval University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Québec, Canada